Novartis Zelmac Co-Promotion Is Possibility, Firm Indicates
Executive Summary
Novartis may consider a co-promotion partner for the irritable bowel syndrome therapy Zelmac (tegaserod) in the U.S., CEO Daniel Vasella indicated during an Aug. 21 conference call with analysts.